Nichi-Iko Takes Share Of Korean Biosimilar Firm Aprogen, Gains Japanese Rights For Remicade And Herceptin Generics
This article was originally published in The Pink Sheet Daily
Executive Summary
Aprogen - founded in 2000 and an affiliate of Korean firm Schnell Biopharmaceuticals - is currently in talks with pharmas in Europe and Central and South America for biosimilar licensing deals.